Seeking Alpha

Amarin (AMRN -0.5%) says the U.S. Patent and Trademark Office gave a Notice of Allowance for two...

Amarin (AMRN -0.5%) says the U.S. Patent and Trademark Office gave a Notice of Allowance for two additional Marine Patent Applications that would protect Vascepa into 2030. The new notice comes on the back of yesterday's announcement that it had received a similar notification for its Vascepa patent titled "Method of Treating Hypertriglyceridemia." MKM Partners notes the significance of these patents, saying they're "clearly important for AMRN to secure a partnership or acquisition."
Comments (2)
  • Holbrook
    , contributor
    Comment (1) | Send Message
     
    I am a long time investor and have held Amarin for about 15 months. It's encouraging to see all of the recent patent approvals for Amarin and comments that patent protection may protect Vascepa out to 2030. I do realize that NCE status for Vascepa is not due until September 14th; however, with the recent patent approvals I would think that NCE approval would be less important in the long run. With brokerage price targets 70%-100% higher, I am somewhat puzzled why Amarin would not be selling in the high teens?
    5 Sep 2012, 04:11 PM Reply Like
  • mitrado
    , contributor
    Comments (1958) | Send Message
     
    "I am somewhat puzzled why Amarin would not be selling in the high teens?"

     

    Because Adam Feuerstein is constantly bashing AMRN (lying, most of the times)... and his minions follow him blindly. :-P

     

    He is a blogger, not a journalist. His opinions are never impartial.
    He earns his living by attacking good companies and making up rumours. He should be in jail, where all criminals should be.

     

    Who is Adam Feuerstein? http://bit.ly/zcz1QE
    11 Sep 2012, 04:51 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|